Skip to content
Valrubicin
Valstar (valrubicin) is a small molecule pharmaceutical. Valrubicin was first approved as Valstar preservative free on 1998-09-25. It is used to treat urinary bladder neoplasms in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
Trade Name
FDA
EMA
Valstar (generic drugs available since 2019-04-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Valrubicin
Tradename
Company
Number
Date
Products
VALSTAR PRESERVATIVE FREEEndoN-020892 RX1998-09-25
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
valstarNew Drug Application2020-12-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
urinary bladder neoplasmsD001749C67
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01D: Cytotoxic antibiotics and related substances
L01DB: Anthracyclines and related substances
L01DB09: Valrubicin
HCPCS
Code
Description
J9357
Injection, valrubicin, intravesical, 200 mg
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PainD010146EFO_0003843R52153110
Postoperative painD010149G89.183216
Rheumatoid arthritisD001172EFO_0000685M06.911
RuptureD01242111
HyperalgesiaD00693011
Sprains and strainsD01318011
Low back painD017116HP_0003419M54.511
Acute painD059787R5211
DysmenorrheaD004412HP_0100607N94.611
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoarthritisD010003EFO_0002506M15-M1922
PancreatitisD010195EFO_0000278K85111
Endoscopic retrograde cholangiopancreatographyD002760111
PharyngitisD010612R07.011
Hallux valgusD006215HP_000182211
Laparoscopic cholecystectomyD01708111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Knee osteoarthritisD020370EFO_0004616M1711
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Platelet aggregationD010974GO_007052711
NeoplasmsD009369C8011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVALRUBICIN
INNvalrubicin
Description
Valrubicin is an anthracycline and a trifluoroacetamide.
Classification
Small molecule
Drug classantineoplastic antibiotics (daunorubicin type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O
Identifiers
PDB
CAS-ID56124-62-0
RxCUI31435
ChEMBL IDCHEMBL1096885
ChEBI ID
PubChem CID454216
DrugBankDB00385
UNII ID2C6NUM6878 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 677 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
13,894 adverse events reported
View more details